Palvella Therapeutics (PVLA) 10-Q4 Nov 222022 Q3 Quarterly reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2022	Nov. 01, 2022
Document Information [Line Items]
Entity Central Index Key	0001583648
Entity Registrant Name	PIERIS PHARMACEUTICALS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-37471
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	30-0784346
Entity Address, Address Line One	255 State Street, 9th Floor
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02109
City Area Code	857
Local Phone Number	246-8998
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	PIRS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		74,406,253

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 48,423	$ 117,764
Short term investments	21,400	0
Accounts receivable	829	3,313
Prepaid expenses and other current assets	7,908	6,548
Total current assets	78,560	127,625
Property and equipment, net	15,897	19,122
Operating lease right-of-use assets	3,399	3,909
Other non-current assets	1,307	2,904
Total assets	99,163	153,560
Current liabilities:
Accounts payable	3,641	8,609
Accrued expenses and other current liabilities	11,382	16,836
Deferred revenues, current portion	18,498	25,116
Total current liabilities	33,521	50,561
Deferred revenue, net of current portion	18,484	38,403
Operating lease liabilities	11,391	13,841
Total liabilities	63,396	102,805
Stockholders’ equity:
Preferred stock	0	0
Common stock	74	72
Additional paid-in capital	317,488	306,998
Accumulated other comprehensive income	524	829
Accumulated deficit	(282,319)	(257,144)
Total stockholders’ equity	35,767	50,755
Total liabilities and stockholders’ equity	$ 99,163	$ 153,560

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue
Customer revenue	$ 5,112	$ 2,783	$ 19,760	$ 20,189
Collaboration revenue	258	1,274	296	2,786
Total revenue	5,370	4,057	20,056	22,975
Operating expenses
Research and development	13,589	18,937	39,602	51,299
General and administrative	3,949	4,132	12,409	12,508
Total operating expenses	17,538	23,069	52,011	63,807
Loss from operations	(12,168)	(19,012)	(31,955)	(40,832)
Other income (expense)
Interest income	241	4	370	10
Grant income	1,468	1,794	4,782	2,590
Other income	723	678	1,628	2,026
Net loss	(9,736)	(16,536)	(25,175)	(36,206)
Other comprehensive income (loss):
Foreign currency translation	(31)	382	(387)	911
Unrealized gain (loss) on available-for-sale securities	(70)	0	82	0
Comprehensive loss	$ (9,837)	$ (16,154)	$ (25,480)	$ (35,295)
Net loss per share
Basic and diluted (in dollars per share)	$ (0.13)	$ (0.24)	$ (0.34)	$ (0.58)
Weighted average number of common shares outstanding
Basic and diluted (in shares)	74,397	67,730	74,080	62,019

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	At the Market Offering [Member] Preferred Stock [Member]	At the Market Offering [Member] Common Stock [Member]	At the Market Offering [Member] Receivables from Stockholder [Member]	At the Market Offering [Member] Additional Paid-in Capital [Member]	At the Market Offering [Member] AOCI Attributable to Parent [Member]	At the Market Offering [Member] Retained Earnings [Member]	At the Market Offering [Member]	Private Placement [Member] Preferred Stock [Member]	Private Placement [Member] Common Stock [Member]	Private Placement [Member] Receivables from Stockholder [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member] AOCI Attributable to Parent [Member]	Private Placement [Member] Retained Earnings [Member]	Private Placement [Member]	Conversion of Preferred Stock [Member] Preferred Stock [Member]	Conversion of Preferred Stock [Member] Common Stock [Member]	Conversion of Preferred Stock [Member] Receivables from Stockholder [Member]	Conversion of Preferred Stock [Member] Additional Paid-in Capital [Member]	Conversion of Preferred Stock [Member] AOCI Attributable to Parent [Member]	Conversion of Preferred Stock [Member] Retained Earnings [Member]	Conversion of Preferred Stock [Member]	Conversion of Preferred Stock [Member] Preferred Stock [Member]	Conversion of Preferred Stock [Member] Common Stock [Member]	Conversion of Preferred Stock [Member] Receivables from Stockholder [Member]	Conversion of Preferred Stock [Member] Additional Paid-in Capital [Member]	Conversion of Preferred Stock [Member] AOCI Attributable to Parent [Member]	Conversion of Preferred Stock [Member] Retained Earnings [Member]	Conversion of Preferred Stock [Member]	Conversion of Series E Preferred Stock [Member] Preferred Stock [Member]	Conversion of Series E Preferred Stock [Member] Common Stock [Member]	Conversion of Series E Preferred Stock [Member] Receivables from Stockholder [Member]	Conversion of Series E Preferred Stock [Member] Additional Paid-in Capital [Member]	Conversion of Series E Preferred Stock [Member] AOCI Attributable to Parent [Member]	Conversion of Series E Preferred Stock [Member] Retained Earnings [Member]	Conversion of Series E Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Receivables from Stockholder [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2020																																				14	56,003
Balance at Dec. 31, 2020																																				$ 0	$ 56	$ 0	$ 242,672	$ (295)	$ (211,406)	$ 31,027
Net loss																																				0	0	0	0	0	(36,206)	(36,206)
Foreign currency translation adjustment																																				0	0	0	0	911	0	911
Stock based compensation expense																																				$ 0	$ 0	0	3,895	0	0	3,895
Issuance of common stock resulting from exercise of stock options (in shares)																																				0	412
Issuance of common stock resulting from exercise of stock options																																				$ 0	$ 0	0	858	0	0	858
Issuance of common stock (in shares)	0	7,558						0	7,290
Issuance of common stock	$ 0	$ 8	$ (1,814)	$ 35,328	$ 0	$ 0	$ 33,522	$ 0	$ 8	$ 0	$ 18,905	$ 0	$ 0	$ 18,913
Issuance of common stock resulting from purchase of employee stock purchase plan shares (in shares)																																				0	40
Issuance of common stock resulting from purchase of employee stock purchase plan shares																																				$ 0	$ 0	0	96	0	0	96
Issuance of common stock resulting from exercise of warrants (in shares)																																				0	1,391
Issuance of common stock resulting from exercise of warrants																																				$ 0	$ 1	0	836	0	0	837
Issuance of common stock resulting from conversion of stock (in shares)																						(4)								(5,000)
Issuance of common stock resulting from conversion of stock																						$ 0	$ 4	$ 0	$ (4)	$ 0	$ 0	$ 0	$ 0	$ (5)	$ 0	$ 5	$ 0	$ 0	$ 0
Conversion of Stock, Shares Issued (in shares)																							3,812						5
Balance (in shares) at Sep. 30, 2021																																				16	71,505
Balance at Sep. 30, 2021																																				$ 0	$ 72	(1,814)	302,591	616	(247,612)	53,853
Balance (in shares) at Jun. 30, 2021																																				16	66,679
Balance at Jun. 30, 2021																																				$ 0	$ 67	0	277,496	234	(231,076)	46,721
Net loss																																				0	0	0	0	0	(16,536)	(16,536)
Foreign currency translation adjustment																																				0	0	0	0	382	0	382
Stock based compensation expense																																				$ 0	$ 0	0	1,370	0	0	1,370
Issuance of common stock resulting from exercise of stock options (in shares)																																				0	272
Issuance of common stock resulting from exercise of stock options																																				$ 0	$ 0	0	566	0	0	566
Issuance of common stock (in shares)	0	4,554
Issuance of common stock	$ 0	$ 5	(1,814)	23,159	0	0	21,350
Balance (in shares) at Sep. 30, 2021																																				16	71,505
Balance at Sep. 30, 2021																																				$ 0	$ 72	(1,814)	302,591	616	(247,612)	53,853
Balance (in shares) at Dec. 31, 2021																																				16	72,222
Balance at Dec. 31, 2021																																				$ 0	$ 72	0	306,998	829	(257,144)	50,755
Net loss																																				0	0	0	0	0	(25,175)	(25,175)
Foreign currency translation adjustment																																				0	0	0	0	(387)	0	(387)
Stock based compensation expense																																				$ 0	$ 0	0	3,453	0	0	3,453
Issuance of common stock resulting from exercise of stock options (in shares)																																				0	46
Issuance of common stock resulting from exercise of stock options																																				$ 0	$ 0	0	95	0	0	95
Issuance of common stock (in shares)	0	2,069
Issuance of common stock	$ 0	$ 2	0	6,838	0	0	6,840
Unrealized loss on investments															$ 0	$ 0	$ 0	$ 0	$ 82	$ 0	$ 82
Issuance of common stock resulting from purchase of employee stock purchase plan shares (in shares)																																				0	69
Issuance of common stock resulting from purchase of employee stock purchase plan shares																																				$ 0	$ 0	0	104	0	0	104
Issuance of common stock resulting from conversion of stock (in shares)																0
Conversion of Stock, Shares Issued (in shares)															0
Balance (in shares) at Sep. 30, 2022																																				16	74,406
Balance at Sep. 30, 2022																																				$ 0	$ 74	0	317,488	524	(282,319)	35,767
Balance (in shares) at Jun. 30, 2022																																				16	74,257
Balance at Jun. 30, 2022																																				$ 0	$ 74	0	316,249	625	(272,583)	44,365
Net loss																																				0	0	0	0	0	(9,736)	(9,736)
Foreign currency translation adjustment																																				0	0	0	0	(31)	0	(31)
Stock based compensation expense																																				0	0	0	974	0	0	974
Issuance of common stock (in shares)	0	0
Issuance of common stock																																				$ 0	$ 0	0	265	0	0	265
Unrealized loss on investments	$ 0	$ 0	$ 0	$ 0	$ (70)	$ 0	$ (70)
Balance (in shares) at Sep. 30, 2022																																				16	74,406
Balance at Sep. 30, 2022																																				$ 0	$ 74	$ 0	$ 317,488	$ 524	$ (282,319)	$ 35,767

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
At the Market Offering [Member]
Stock issuance costs		$ 0.3	$ 1.2
Private Placement [Member]
Stock issuance costs			$ 0.1
Stock issuance costs	$ 0.8

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities:
Net loss	$ (25,175)	$ (36,206)
Adjustments to reconcile net loss to net cash (used in) operating activities:
Depreciation and amortization	2,195	1,850
Right-of-use asset (accretion) amortization	0	(70)
Stock-based compensation	3,453	3,895
Realized investment gains	(299)	0
Other non-cash transactions	216	26
Changes in operating assets and liabilities	(27,389)	33,789
Net cash provided by (used in) operating activities	(46,999)	3,284
Investing activities:
Purchases of property and equipment	(1,052)	(607)
Proceeds from maturity of investments	21,900	0
Purchases of investments	(43,191)	0
Net cash (used in) investing activities	(22,343)	(607)
Financing activities:
Proceeds from exercise of stock options	95	858
Proceeds from exercise of warrants	0	837
Proceeds from employee stock purchase plan	104	96
Proceeds from issuance of common stock from private placement, net of issuance costs	0	18,913
Proceeds from issuance of common stock resulting from ATM sales, net of $0.3 million in transaction costs	6,922	33,522
Net cash provided by financing activities	7,121	54,226
Effect of exchange rate change on cash and cash equivalents	(7,120)	(2,287)
Net decrease in cash and cash equivalents	(69,341)	54,616
Cash and cash equivalents at beginning of period	117,764	70,436
Cash and cash equivalents at end of period	48,423	125,052
Supplemental cash flow disclosures:
Net unrealized gain on investments	82	0
Property and equipment included in accounts payable	$ 31	$ 0

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Parentheticals) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
At the Market Offering [Member] \| Common Stock [Member]
Stock issuance costs	$ 0.3	$ 0.3

Note 1 - Corporate Information

Note 1 - Corporate Information	9 Months Ended
Note 1 - Corporate Information	Sep. 30, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Corporate Information Pieris Pharmaceuticals, Inc. was founded in May 2013, 2001 December 2014. Pieris’ clinical pipeline includes an inhaled IL- 4Rα 4 1BB L1. The Company’s core Anticalin technology and platform was developed in Germany, and the Company has partnership arrangements with several major multi-national pharmaceutical companies. The Company is subject to risks common to companies in the biotechnology industry, including but not may third As of September 30, 2022 three September 30, 2022 2021 nine September 30, 2022 2021 September 30, 2022 The future success of the Company is dependent on its ability to identify and develop its product candidates, expand its corporate infrastructure and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expenses to support such research and development. The Company has several research and development programs underway in varying stages of development, and it expects that these programs will continue to require increasing amounts of cash for development, conducting clinical trials, and testing and manufacturing of product material. Cash necessary to fund operations will increase significantly over the next several years as the Company continues to conduct these activities necessary to pursue governmental regulatory approval of clinical-stage programs and other product candidates. The Company plans to raise additional capital to fulfill its operating and capital requirements through public or private equity financings, utilization of its current “at the market offering” program, or ATM Program, strategic collaborations, licensing arrangements, government grants and/or the achievement of milestones under its collaborative agreements. The funding requirements of the Company’s operating plans, however, are based on estimates that are subject to risks and uncertainties and may no may The Company believes that its currently available funds will be sufficient to fund the Company’s operations through at least the next twelve 10 may may

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
Note 2 - Summary of Significant Accounting Policies	Sep. 30, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 2—Summary 10 December 31, 2021 no nine September 30, 2022 Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements included herein have been prepared by the Company in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, for interim financial information and pursuant to the rules and regulations of the SEC. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments, consisting of normal recurring adjustments, and disclosures considered necessary for a fair presentation of interim period results have been included. Interim results for the three nine September 30, 2022 not may December 31, 2022 10 December 31, 2021 March 2, 2022. Basis of Presentation and Use of Estimates The accompanying condensed consolidated financial statements of Pieris Pharmaceuticals, Inc. and its wholly-owned subsidiaries were prepared in accordance with U.S. GAAP. The condensed consolidated financial statements include the accounts of all subsidiaries. All intercompany balances and transactions have been eliminated. The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not Cash, Cash Equivalents and Investments The Company determines the appropriate classification of its investments at the time of purchase. All liquid investments with original maturities of 90 320, Investments Debt and Equity Securities Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive loss on the Company’s balance sheets. Realized gains and losses are determined using the specific identification method and are included as a component of other income. The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not not Concentration of Credit Risk and Off-Balance Sheet Risk The Company has no not not not Fair Value Measurement The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC Topic 820, Fair Value Measurement and Disclosures not one three • Level 1 • Level 2 not • Level 3 To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial instruments measured at fair value on a recurring basis include cash equivalents and investments (see Note 5 An entity may not Property and Equipment Property and equipment are recorded at acquisition cost, less accumulated depreciation and impairment. Depreciation on property and equipment is calculated using the straight-line method over the remaining estimated useful lives of the assets. Maintenance and repairs to these assets are charged to expenses as occurred. The estimated useful life of the different groups of property and equipment is as follows: Asset Classification Estimated useful life (in years) Leasehold improvements shorter of useful life or remaining life of the lease Laboratory furniture and equipment 8 - 14 Office furniture and equipment 5 - 13 Computer and equipment 3 - 7 Revenue Recognition Pieris has entered into several licensing agreements with collaboration partners for the development of Anticalin therapeutics against a variety of targets. The terms of these agreements provide for the transfer of multiple goods or services which may may no Collaborative Arrangements The Company considers the nature and contractual terms of an arrangement and assesses whether the arrangement involves a joint operating activity pursuant to which it is an active participant and exposed to significant risks and rewards with respect to the arrangement. If the Company is an active participant and exposed to the significant risks and rewards with respect to the arrangement, it accounts for these arrangements pursuant to ASC 808, Collaborative Arrangements 808, not Revenue from Contracts with Customers In accordance with ASC 606, five 1 2 3 4 5 The Company evaluates all promised goods and services within a customer contract and determines which of such goods and services are separate performance obligations. This evaluation includes an assessment of whether the good or service is capable of being distinct and whether the good or service is separable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available. Licensing arrangements are analyzed to determine whether the promised goods or services, which often include licenses, research and development services and governance committee services, are distinct or whether they must be accounted for as part of a combined performance obligation. If the license is considered not Certain contracts contain optional and additional items, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. A contract may not If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price among the performance obligations on a relative standalone selling price basis unless a portion of the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct good or service that forms part of a single performance obligation. The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or, in the case of certain variable consideration, to one may one When a performance obligation is satisfied, revenue is recognized for the amount of the transaction price, excluding estimates of variable consideration that are constrained, that is allocated to that performance obligation on a relative standalone selling price basis. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. Revenue recognized under an arrangement involving a participant that is a customer is presented as Customer Revenue. Milestones and Royalties The Company aggregates milestones into four first There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company’s technology. The Company has thus determined that all research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will not For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Commercial milestones and sales royalties are determined by sales or usage-based thresholds and will be accounted for under the royalty recognition constraint as constrained variable consideration. The Company calculates the maximum amount of potential milestones achievable under each collaboration agreement and discloses such potential future milestones for all current collaborations using such a maximum calculation. Contract Balances The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as a receivable (i.e., accounts receivable). A contract asset is an entity’s right to consideration in exchange for goods or services that the entity has transferred to a customer. The contract liabilities (i.e., deferred revenue) primarily relate to contracts where the Company has received payment but has not In the event of an early termination of a collaboration agreement, any contract liabilities would be recognized in the period in which all Company obligations under the agreement have been fulfilled. Costs to Obtain and Fulfill a Contract with a Customer Certain costs to obtain customer contracts, including success-based fees paid to third 340, Other Assets and Deferred Costs 340. Government Grants The Company recognizes grants from governmental agencies when there is reasonable assurance that the Company will comply with the conditions attached to the grant arrangement and the grant will be received. The Company evaluates the conditions of each grant as of each reporting period to evaluate whether the Company has reached reasonable assurance of meeting the conditions of each grant arrangement and that it is expected that the grant will be received as a result of meeting the necessary conditions. Grants are recognized in the consolidated statements of operations on a systematic basis over the periods in which the Company recognizes the related costs for which the government grant is intended to compensate. Specifically, grant income related to research and development costs is recognized as such expenses are incurred. Grant income is included as a separate caption within Other income (expense), net in the consolidated statements of operations. Leases In accordance with ASU No. 2016 2, 842 842, The Company determines if an arrangement is a lease at inception. The Company’s contracts are determined to contain a lease within the scope of ASC 842 1 no 2 3 At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company’s lease agreements do not may The Company typically only includes an initial lease term in its assessment of a lease agreement. Options to renew a lease are not not Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not Recent Accounting Pronouncements Not In June 2016, No. 2016 13, Financial Instruments - Credit Losses (Topic 326 2016 13. 2016 13 Subsequently, in November 2018, No. 2018 19, Codification Improvements to Topic 326, November 2019, No. 2019 11, Codification Improvements to Topic 326, 2016 13. November 2019 No. 2019 10, Financial Instruments-Credit Losses (Topic 326 815 842 2016 13 three 2016 13 December 15, 2022 The Company has considered other recent accounting pronouncements and concluded that they are either not not

Note 3 - Revenue

Note 3 - Revenue	9 Months Ended
Note 3 - Revenue	Sep. 30, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3. Revenue General The Company has not The Company recognized revenue from the following strategic partnerships and other license agreements (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Seagen $ 155 $ (280 ) $ 3,074 $ 424 AstraZeneca 4,404 1,607 9,026 18,309 Servier 258 1,867 5,223 3,379 Genentech 553 863 2,733 863 Total Revenue $ 5,370 $ 4,057 $ 20,056 $ 22,975 Under the Company’s existing strategic partnerships and other license agreements, the Company could receive the following potential milestone payments (in millions): Research, Development, Regulatory & Commercial Milestones Sales Milestones AstraZeneca $ 702 $ 3,925 Servier 118 88 Seagen 754 450 Boston Pharmaceuticals 88 265 Genentech 834 600 Total potential milestone payments $ 2,496 $ 5,328 Strategic Partnerships Genentech On May 19, 2021, may Under the terms of the Genentech Agreement, the Company is responsible for discovery and preclinical development of two two Unless earlier terminated, the term of the Genentech Agreement continues until no may not not nine first first While the Genentech Agreement allows for up to four research programs, only two research programs are initially identified and committed in the Genentech Agreement. To reach a total of up to four research programs, the Company has granted Genentech options to nominate two additional collaboration targets of their choosing, subject to the legal availability of the target to be researched. Genentech will have three no The arrangement with Genentech provides for the transfer of the following goods or services: (i) exclusive research and commercial license for the collaboration programs, (ii) a non-exclusive platform improvement license, (iii) research and development services, (iv) participation in a governance committee, and (v) replacement target options on the first Management evaluated all of the promised goods or services within the contract and determined which such goods and services were separate performance obligations. The Company determined that the licenses granted, at arrangement inception, should be combined with the research and development services to be provided for the related target programs as they are not third not not As a result, management concluded there were five separate performance obligations at the inception of the Genentech Agreement: (i) two combined performance obligations, each comprised of an exclusive research and commercial license, a non-exclusive platform improvement license, and research and development services for the first first The Company allocated consideration to the performance obligations based on the relative proportion of their standalone selling prices. The Company developed standalone selling prices for licenses by applying a risk adjusted, net present value, estimate of future potential cash flows approach, which included the cost of obtaining research and development services at arm’s length from a third The transaction price at inception is comprised of fixed consideration of $20.0 million in upfront fees and was allocated to each of the performance obligations based on the relative proportion of their standalone selling prices. The amounts allocated to the performance obligations for the two research programs will be recognized on a proportional performance basis through the completion of each respective estimated research term of the individual research programs. The amounts allocated to the material right for the target options will be recognized either at the time the material right expires or, if exercised, on a proportional performance basis over the estimated research term for that program along with any remaining deferred revenue associated with the replacement target. The amounts allocated to the participation on the committee will be recognized on a straight-line basis over the anticipated research term for all research programs. As of September 30, 2022 Under the Genentech Agreement, the Company is eligible to receive various research, development, commercial and sales milestones. There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company’s technology. The Company has determined that all other research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will not As of September 30, 2022 Boston Pharmaceuticals On April 24, 2021, 342/BOS 342, 4 1BB/GPC3 TM (antibody-Anticalin fusion) protein. Under the term of the BP Agreement, Boston Pharmaceuticals exclusively licensed worldwide right to PRS- 342. 342 The term of the BP Agreement ends upon the expiration of all of Boston Pharmaceuticals’ payment obligations thereunder. The BP Agreement may nine may may may The Company does not 342, Management evaluated all of the promised goods or services within the BP Agreement and determined which such goods and services were separate performance obligations. The Company determined that the licenses granted, at arrangement inception, should be combined with the transfer of know-how, materials and the product cell line license. Boston Pharmaceuticals could not As a result, management concluded there was only one The amounts allocated to the performance obligations did not 342. fourth 2021. December 31, 2021 no Seagen On February 8, 2018, Under the terms of the Seagen Agreements, the companies will pursue multiple Mabcalin proteins during the research phase. The Seagen Agreements provide Seagen a base option to select up to three programs for further development. Prior to the initiation of a pivotal trial, the Company may second may The Seagen Platform License grants Seagen a non-exclusive license to certain intellectual property related to the Anticalin platform technology. Upon signing the Seagen Agreements, Seagen paid the Company a $30.0 million upfront fee and an additional $4.9 million was estimated to be paid for research and development services as reimbursement to the Company through the end of the research term. In addition, the Company may The term of each of the Seagen Agreements ends upon the expiration of all of Seagen’s payment obligations under each such agreement. The Seagen Collaboration Agreement may may may may may may The Company determined that the Seagen Agreements should be combined and evaluated as a single arrangement under ASC 606 Management evaluated all of the promised goods or services within the contract and determined which such goods and services were separate performance obligations. The Company determined that the licenses granted, at arrangement inception, should be combined with the research and development services to be provided for the related antibody target programs as they are not third not not As a result, management concluded there were six separate performance obligations at the inception of the Seagen Agreements: (i) three combined performance obligations, each comprised of a non-exclusive platform technology license, a co-exclusive candidate research license, and research and development services for the first first second no The Company allocated consideration to the performance obligations based on the relative proportion of their standalone selling prices. The Company developed standalone selling prices for licenses by applying a risk adjusted, net present value, estimate of future potential cash flows approach, which included the cost of obtaining research and development services at arm’s length from a third The transaction price at inception is comprised of fixed consideration of $30.0 million in upfront fees and variable consideration of $4.9 million of estimated research and development services to be reimbursed as research and development occurs through the research term. The $30.0 million upfront fee, which represents the fixed consideration in the transaction price, was allocated to each of the performance obligations based on the relative proportion of their standalone selling prices. The $4.9 million in variable consideration related to the research and development services is allocated specifically to the three target program performance obligations based upon the budgeted services for each program. The amounts allocated to the performance obligations for the three research programs will be recognized on a proportional performance basis through the completion of each respective estimated research term of the individual research programs. The amounts allocated to the material right for the antibody target swap option will be recognized either at the time the material right expires or, if exercised, on a proportional performance basis over the estimated research term for that program. The amounts allocated to the participation on each of the committees will be recognized on a straight-line basis over the anticipated research term for all research programs. As of September 30, 2022 September 30, 2022 On March 24, 2021, HER2 HER2 2 August 2022 second Under the Second Seagen Amendment, Pieris’ option to co-develop and co-commercialize the second one 4 2 may 606 The Company has concluded that the Combination Study Agreement is within the scope of ASC 808, two 808 not may 730, Research and Development no Under the Seagen Agreements, the Company is eligible to receive other various research, development, commercial and sales milestones. There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company’s technology. With the exception of the previously discussed achieved milestone, the Company has determined that all other research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will not As of September 30, 2022 AstraZeneca On May 2, 2017, June 10, 2017, 1976. In addition to the Company’s lead inhaled drug candidate, elarekibep (formerly known as PRS- 060/AZD1402 1 2a 2a The term of each of the AstraZeneca Agreements ends upon the expiration of all of AstraZeneca’s payment obligations under such agreement. The AstraZeneca Collaboration Agreement may may may not not may may may At inception, AstraZeneca is granted the following licenses: (i) research and development license for the AstraZeneca Lead Product, (ii) commercial license for the AstraZeneca Lead Product, (iii) individual research licenses for each of the four AstraZeneca Collaboration Products, (iv) individual commercial licenses for each of the four AstraZeneca Collaboration Products, and (v) individual non-exclusive platform technology licenses for the AstraZeneca Lead Product and the four AstraZeneca Collaboration Products. AstraZeneca will be granted individual development licenses for each of the four AstraZeneca Collaboration Products upon completion of the initial discovery of Anticalin proteins. The collaboration will be managed on an overall basis by a Joint Steering Committee, or JSC, formed by an equal number of representatives from the Company and AstraZeneca. In addition to the JSC, the AstraZeneca Collaboration Agreement also requires each party to designate an alliance manager to facilitate communication and coordination of the parties’ activities under the agreement, and further requires participation of both parties on a joint development committee, or JDC, and a commercialization committee. The responsibilities of these committees vary, depending on the stage of development and commercialization of each product. Under the AstraZeneca Agreements, the Company received an upfront, non-refundable payment of $45.0 million. In addition, the Company will receive payments to conduct a phase 1 may The Company determined that the AstraZeneca Agreements should be combined and evaluated as a single arrangement under ASC 606 1 x 2a may Management evaluated all of the promised goods or services within the contract and determined which such goods and services were separate performance obligations. The Company determined that the licenses granted for the AstraZeneca Lead Product at the inception of the arrangement should be combined with the research services related to the AstraZeneca Lead Product and that the licenses granted for the AstraZeneca Collaboration Products should be combined with the research services for the AstraZeneca Collaboration Products, as the licenses are not third not not 1 2a 1 2a not As a result, management concluded that there were 16 performance obligations: (i) combined performance obligation comprised of a non-exclusive platform technology license, research and development license, and commercial licenses for the AstraZeneca Lead Product and research services for the AstraZeneca Lead Product, (ii) combined performance obligation comprised of development and manufacturing services, and technology transfer services for the AstraZeneca Lead Product, (iii) committee participation, (iv-vii) four combined performance obligations each comprised of a non-exclusive platform technology license, research licenses, and research services for each AstraZeneca Collaboration Product, (viii-xi) four performance obligations comprised of a material right to acquire the development licenses granted for the AstraZeneca Collaboration Products, (xii-xv) four performance obligations comprised of the commercial licenses granted for the AstraZeneca Collaboration Products and (xvi) phase 2a The Company allocated consideration to the performance obligations based on the relative proportion of their standalone selling prices. The Company developed standalone selling prices for licenses and corresponding research services by applying a risk adjusted, net present value, estimate of future potential cash flow approach, which included the cost of obtaining research services at arm’s length from a third The Company developed its standalone selling price for committee participation by using management’s estimate of the anticipated participation hours multiplied by a market rate for comparable participants. The Company developed its standalone selling price for the commercial licenses and material rights granted on the development licenses by probability weighting multiple cash flow scenarios using the income approach. The transaction price was comprised of fixed consideration of $45.0 million in upfront fees and variable consideration of (i) $14.2 million in estimated phase 1 1 December 2017, 2a 1 1 2a The amounts allocated to the license performance obligation for the AstraZeneca Lead Product and the four performance obligations for the four research licenses for AstraZeneca Collaboration Products will be recognized on a proportional performance basis as the activities are conducted over the life of the arrangement. The amounts allocated to the performance obligation for phase 1 2a 2a five September 30, 2022 Additionally, the Company evaluated payments required to be made between both parties as a result of the shared development costs of the AstraZeneca Lead Product and the two AstraZeneca Collaboration Products for which the Company has a co-development option. The Company will classify payments made as a reduction of revenue and will classify payments received as revenue in the period they are earned. Under the AstraZeneca Agreements, the Company is eligible to receive various research, development, commercial and sales milestones. There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company’s technology. The Company has thus determined that all research and development milestones, other than the phase 1 December 2017 606, not On March 29, 2021, 1 No. 1 May 2, 2017, 2 No. 2 May 2, 2017, No. 1 September 14, 2020, In connection with the Amended Collaboration Agreement, the Company and AstraZeneca entered into a subscription agreement, or the AstraZeneca Subscription Agreement, pursuant to which the Company agreed to issue to AstraZeneca, and AstraZeneca agreed to acquire from the Company, 3,584,230 shares of the Company’s common stock for a total purchase price of $10.0 million, or $2.79 per share, in a private placement transaction pursuant to Section 4 2 April 1, 2021 606 Also in March 2021, 2a 606 no 2a March 31, 2021. In January 2022, not In August 2022, May 2, 2017, two December 2023. second As of September 30, 2022 The Company incurred $1.6 million of third 606, 340. September 30, 2022 three September 30, 2022 2021 nine September 30, 2022 2021 Servier In 2017, Each party is responsible for an agreed upon percentage of shared costs, as set forth in the budget for the collaboration plan, and as further discussed below. Since inception, three of the five initially committed programs have been discontinued, including the initial lead. The Company does not three 344/S095012, 4 1BB/PD L1 344/S095012, may 352/S095025, L1 OX40, The Servier Agreements are managed on an overall basis by a joint executive committee, or JEC, formed by an equal number of members from the Company and Servier. Decisions by the JEC will be made by consensus; however, in the event of a disagreement, each party will have final decision-making authority as it relates to the applicable territory in which such party has commercialization rights for the applicable product. In addition to the JEC, the Servier Collaboration Agreement requires the participation of both parties on: (i) a JSC, (ii) a JDC, (iii) a joint intellectual property committee, or JIPC, and (iv) a joint research committee, or JRC. The responsibilities of these committees vary, depending on the stage of development and commercialization of the Collaboration Products. Under the Servier Agreements, the Company received an upfront, non-refundable payment of €30.0 344/S095012 €3.3 The term of each Servier Agreement ends upon the expiration of all of Servier’s payment obligations under such Servier Agreement. The Servier Agreements may not may may As the Company and Servier are considered to be active participants in the Servier Agreements and are exposed to significant risks and rewards, certain units of account within the Servier Agreements are within the scope of ASC 808. Upon signing the Servier Agreements, management evaluated all of the promised goods or services within the contract and determined which goods and services were separate performance obligations. Of the initial 10 performance obligations identified at the inception of the Servier Agreements, only three are still ongoing as of September 30, 2022 808: • one 344/S095012, • one • one 344/S095012 Revenue recognized associated with these performance obligations are presented as Collaboration Revenue within the Statement of Operations. The following performance obligation is within the scope of ASC 606: 352/S095012 three March 31, 2022 The transaction price at inception is comprised of the fixed upfront fee of €30.0 The amounts allocated to the performance obligation for the research and development licenses for PRS- 344/S095012 344/S095012 one 344/S095012 September 30, 2022 Additionally, the Company evaluated payments required to be made between both parties as a result of the shared development costs of the Initial Lead and Collaboration Products. The Company will classify payments made as a reduction of revenue and will classify payments received as revenue, in the period they are earned. Under the Servier Agreements, the Company is eligible to receive various research, development, commercial and sales milestones as well as tiered royalties up to low double digits on the sales of commercialized products in the Servier territories. There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company’s technology. The Company has thus determined that research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will not During the nine September 30, 2022 352/S095025, As of September 30, 2022 The Company incurred costs to obtain the contract with Servier. Upon adoption of ASC 606, third 340. September 30, 2022 three September 30, 2022 2021 nine September 30, 2022 2021 Contract Balances The Company receives payments from its collaboration partners based on payments established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until such time as the Company satisfies its performance obligations under each arrangement. A contract asset is a conditional right to consideration in exchange for goods or services that the Company has transferred to a customer. Amounts are recorded as accounts receivable when the Company’s right is unconditional. There were no additions to deferred revenue during the three nine September 30, 2022 three nine September 30, 2022

Note 4 - Grant Income

Note 4 - Grant Income	9 Months Ended
Note 4 - Grant Income	Sep. 30, 2022
Notes to Financial Statements
Government Assistance [Text Block]	4. Grant Income One of the Company's proprietary respiratory assets is PRS- 220, June 2021, €14.2 June 2021) 2 19 The Bavarian Grant provides partial reimbursement for qualifying research and development activities on PRS- 220, 1 August 2023, may 220, August 2023.

Note 5 - Cash, Cash Equivalents

Note 5 - Cash, Cash Equivalents and Investments	9 Months Ended
Note 5 - Cash, Cash Equivalents and Investments	Sep. 30, 2022
Notes to Financial Statements
Cash, Cash Equivalents, and Marketable Securities [Text Block]	5. Cash, cash equivalents and investments As of September 30, 2022 December 31, 2021 2 September 30, 2022 December 31, 2021 Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) September 30, 2022 Money market funds, included in cash equivalents $ 25,183 $ 25,183 $ — $ — Investments - US treasuries 2,674 2,674 — — Investments - Foreign treasuries 894 894 — — Investments - Asset-backed securities 497 — 497 — Investments - Corporate bonds 17,335 — 17,335 — Total $ 46,583 $ 28,751 $ 17,832 $ — Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) December 31, 2021 Money market funds, included in cash equivalents $ 56,885 $ 56,885 $ — $ — Total $ 56,885 $ 56,885 $ — $ — Cash equivalents and marketable securities have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third third not September 30, 2022 Investments at September 30, 2022 Contractual maturity (in days) Amortized Cost Unrealized gains Unrealized losses Fair Value Investments US treasuries 6-153 $ 2,676 $ — $ (2 ) $ 2,674 Foreign treasuries 166 898 — (4 ) 894 Asset-backed securities 107 500 — (3 ) 497 Corporate bonds 1-251 17,244 126 (35 ) 17,335 Total $ 21,318 $ 126 $ (44 ) $ 21,400 The Company recorded realized gains from the maturity of available-for-sale securities of $0.2 million and $0.3 million during the three nine September 30, 2022 three nine September 30, 2021 As of September 30, 2022 no

Note 6 - Property and Equipment

Note 6 - Property and Equipment, Net	9 Months Ended
Note 6 - Property and Equipment, Net	Sep. 30, 2022
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6. Property and equipment, net Property and equipment are summarized as follows (in thousands): September 30, December 31, 2022 2021 Laboratory furniture and equipment $ 10,759 $ 11,354 Office furniture and equipment 1,712 1,959 Computer equipment 348 396 Leasehold improvements 11,397 13,130 Property and equipment, cost 24,216 26,839 Accumulated depreciation (8,319 ) (7,717 ) Property and equipment, net $ 15,897 $ 19,122

Note 7 - Accrued Expenses

Note 7 - Accrued Expenses	9 Months Ended
Note 7 - Accrued Expenses	Sep. 30, 2022
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	7. Accrued Expenses Accrued expenses and other current liabilities consisted of the following (in thousands): September 30, December 31, 2022 2021 Research and development fees $ 5,036 $ 5,682 Compensation expense 3,248 3,581 Accrued license obligations 131 1,541 Accrued accounts payable 1,560 2,980 Lease liabilities 826 1,049 Other current liabilities 581 393 Collaboration cost-sharing obligation — 1,610 Total $ 11,382 $ 16,836

Note 8 - Net Loss Per Share

Note 8 - Net Loss Per Share	9 Months Ended
Note 8 - Net Loss Per Share	Sep. 30, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	8. Net Loss per Share Basic net loss per share is calculated by dividing net income loss by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, preferred stock, stock options and warrants are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented. As of September 30, 2022 2021

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	9 Months Ended
Note 9 - Stockholders' Equity	Sep. 30, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. Stockholders Equity The Company had 300,000,000 shares authorized and 74,406,253 and 72,222,661 shares of common stock issued and outstanding as of September 30, 2022 December 31, 2021 The Company had 10,000,000 shares authorized and 15,617 shares of preferred stock issued and outstanding as of September 30, 2022 December 31, 2021 • Series A Convertible, 85 shares issued and outstanding at September 30, 2022 December 31, 2021 • Series B Convertible, 4,026 shares issued and outstanding at September 30, 2022 December 31, 2021 • Series C Convertible, 3,506 shares issued and outstanding at September 30, 2022 December 31, 2021 • Series D Convertible, 3,000 shares issued and outstanding at September 30, 2022 December 31, 2021 • Series E Convertible, 5,000 shares issued and outstanding at September 30, 2022 December 31, 2021 2020 At the 2020 2020 2020 2020 2020 2020 2019 2019 no 2019 2020 2019 2020 At the 2021 June 25, 2021, first 2020 2020 2022 June 22, 2022, second 2020 2020 Series E Preferred Stock Conversion On May 20, 2021, Open Market Sales Agreements In August 2021, may 3 August 2021. For the nine September 30, 2022

Note 10 - Leases

Note 10 - Leases	9 Months Ended
Note 10 - Leases	Sep. 30, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	10. Leases In August 2015, July 2021, December 31, 2022, not In October 2018, February 2020 12.5 October 2024. first not may may not Monthly base rent for the initial 105,000 square feet of the leased property, including parking spaces, will total approximately $0.2 million per month. In addition to the base rent, Pieris GmbH is also responsible for certain administrative and operational costs in accordance with the Hallbergmoos Lease. Pieris GmbH provided a security deposit of $0.8 million as required by the Hallbergmoos Lease. The Company will serve as a guarantor for the Hallbergmoos Lease. The Hallbergmoos Lease included $11.5 million of tenant improvements allowance for normal tenant improvements, for which construction began in March 2019. 842. The following table summarizes operating lease costs included in operating expenses (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating lease costs $ 314 $ 370 $ 943 $ 1,126 Variable lease costs (1) 148 198 446 562 Total lease cost $ 462 $ 568 $ 1,389 $ 1,688 ( 1 The following table summarizes the weighted-average remaining lease term and discount rate: As of September 30, 2022 Weighted-average remaining lease term (years) 9.8 Weighted-average discount rate 10.5 % Cash paid for amounts included in the measurement of the lease liabilities were $0.5 million and $0.6 million, respectively, for the three September 30, 2022 2021 nine September 30, 2022 2021 As of September 30, 2022 Total 2022 $ 545 2023 1,934 2024 1,934 2025 1,934 2026 1,934 Thereafter 10,797 Total undiscounted lease payments 19,078 Less: present value adjustment (6,861 ) Present value of lease liabilities $ 12,217

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	The accompanying condensed consolidated financial statements of Pieris Pharmaceuticals, Inc. and its wholly-owned subsidiaries were prepared in accordance with U.S. GAAP. The condensed consolidated financial statements include the accounts of all subsidiaries. All intercompany balances and transactions have been eliminated.
Use of Estimates, Policy [Policy Text Block]	The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents and Investments The Company determines the appropriate classification of its investments at the time of purchase. All liquid investments with original maturities of 90 320, Investments Debt and Equity Securities Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive loss on the Company’s balance sheets. Realized gains and losses are determined using the specific identification method and are included as a component of other income. The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not not
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Off-Balance Sheet Risk The Company has no not not not
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurement The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC Topic 820, Fair Value Measurement and Disclosures not one three • Level 1 • Level 2 not • Level 3 To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial instruments measured at fair value on a recurring basis include cash equivalents and investments (see Note 5 An entity may not
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at acquisition cost, less accumulated depreciation and impairment. Depreciation on property and equipment is calculated using the straight-line method over the remaining estimated useful lives of the assets. Maintenance and repairs to these assets are charged to expenses as occurred. The estimated useful life of the different groups of property and equipment is as follows: Asset Classification Estimated useful life (in years) Leasehold improvements shorter of useful life or remaining life of the lease Laboratory furniture and equipment 8 - 14 Office furniture and equipment 5 - 13 Computer and equipment 3 - 7
Revenue [Policy Text Block]	Revenue Recognition Pieris has entered into several licensing agreements with collaboration partners for the development of Anticalin therapeutics against a variety of targets. The terms of these agreements provide for the transfer of multiple goods or services which may may no Collaborative Arrangements The Company considers the nature and contractual terms of an arrangement and assesses whether the arrangement involves a joint operating activity pursuant to which it is an active participant and exposed to significant risks and rewards with respect to the arrangement. If the Company is an active participant and exposed to the significant risks and rewards with respect to the arrangement, it accounts for these arrangements pursuant to ASC 808, Collaborative Arrangements 808, not Revenue from Contracts with Customers In accordance with ASC 606, five 1 2 3 4 5 The Company evaluates all promised goods and services within a customer contract and determines which of such goods and services are separate performance obligations. This evaluation includes an assessment of whether the good or service is capable of being distinct and whether the good or service is separable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available. Licensing arrangements are analyzed to determine whether the promised goods or services, which often include licenses, research and development services and governance committee services, are distinct or whether they must be accounted for as part of a combined performance obligation. If the license is considered not Certain contracts contain optional and additional items, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. A contract may not If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price among the performance obligations on a relative standalone selling price basis unless a portion of the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct good or service that forms part of a single performance obligation. The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or, in the case of certain variable consideration, to one may one When a performance obligation is satisfied, revenue is recognized for the amount of the transaction price, excluding estimates of variable consideration that are constrained, that is allocated to that performance obligation on a relative standalone selling price basis. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. Revenue recognized under an arrangement involving a participant that is a customer is presented as Customer Revenue. Milestones and Royalties The Company aggregates milestones into four first There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company’s technology. The Company has thus determined that all research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will not For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Commercial milestones and sales royalties are determined by sales or usage-based thresholds and will be accounted for under the royalty recognition constraint as constrained variable consideration. The Company calculates the maximum amount of potential milestones achievable under each collaboration agreement and discloses such potential future milestones for all current collaborations using such a maximum calculation. Contract Balances The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as a receivable (i.e., accounts receivable). A contract asset is an entity’s right to consideration in exchange for goods or services that the entity has transferred to a customer. The contract liabilities (i.e., deferred revenue) primarily relate to contracts where the Company has received payment but has not In the event of an early termination of a collaboration agreement, any contract liabilities would be recognized in the period in which all Company obligations under the agreement have been fulfilled. Costs to Obtain and Fulfill a Contract with a Customer Certain costs to obtain customer contracts, including success-based fees paid to third 340, Other Assets and Deferred Costs 340.
Government Assistance [Policy Text Block]	Government Grants The Company recognizes grants from governmental agencies when there is reasonable assurance that the Company will comply with the conditions attached to the grant arrangement and the grant will be received. The Company evaluates the conditions of each grant as of each reporting period to evaluate whether the Company has reached reasonable assurance of meeting the conditions of each grant arrangement and that it is expected that the grant will be received as a result of meeting the necessary conditions. Grants are recognized in the consolidated statements of operations on a systematic basis over the periods in which the Company recognizes the related costs for which the government grant is intended to compensate. Specifically, grant income related to research and development costs is recognized as such expenses are incurred. Grant income is included as a separate caption within Other income (expense), net in the consolidated statements of operations.
Lessee, Leases [Policy Text Block]	Leases In accordance with ASU No. 2016 2, 842 842, The Company determines if an arrangement is a lease at inception. The Company’s contracts are determined to contain a lease within the scope of ASC 842 1 no 2 3 At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company’s lease agreements do not may The Company typically only includes an initial lease term in its assessment of a lease agreement. Options to renew a lease are not not Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Not In June 2016, No. 2016 13, Financial Instruments - Credit Losses (Topic 326 2016 13. 2016 13 Subsequently, in November 2018, No. 2018 19, Codification Improvements to Topic 326, November 2019, No. 2019 11, Codification Improvements to Topic 326, 2016 13. November 2019 No. 2019 10, Financial Instruments-Credit Losses (Topic 326 815 842 2016 13 three 2016 13 December 15, 2022 The Company has considered other recent accounting pronouncements and concluded that they are either not not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Property, Plant and Equipment, Estimated Useful Life [Table Text Block]	Asset Classification Estimated useful life (in years) Leasehold improvements shorter of useful life or remaining life of the lease Laboratory furniture and equipment 8 - 14 Office furniture and equipment 5 - 13 Computer and equipment 3 - 7

Note 3 - Revenue (Tables)

Note 3 - Revenue (Tables)	9 Months Ended
Note 3 - Revenue (Tables)	Sep. 30, 2022
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Seagen $ 155 $ (280 ) $ 3,074 $ 424 AstraZeneca 4,404 1,607 9,026 18,309 Servier 258 1,867 5,223 3,379 Genentech 553 863 2,733 863 Total Revenue $ 5,370 $ 4,057 $ 20,056 $ 22,975
Revenue From Contract With Customer, Milestone Payments [Table Text Block]	Research, Development, Regulatory & Commercial Milestones Sales Milestones AstraZeneca $ 702 $ 3,925 Servier 118 88 Seagen 754 450 Boston Pharmaceuticals 88 265 Genentech 834 600 Total potential milestone payments $ 2,496 $ 5,328

Note 5 - Cash, Cash Equivalen_2

Note 5 - Cash, Cash Equivalents and Investments (Tables)	9 Months Ended
Note 5 - Cash, Cash Equivalents and Investments (Tables)	Sep. 30, 2022
Notes Tables
Cash, Cash Equivalents and Investments [Table Text Block]	Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) September 30, 2022 Money market funds, included in cash equivalents $ 25,183 $ 25,183 $ — $ — Investments - US treasuries 2,674 2,674 — — Investments - Foreign treasuries 894 894 — — Investments - Asset-backed securities 497 — 497 — Investments - Corporate bonds 17,335 — 17,335 — Total $ 46,583 $ 28,751 $ 17,832 $ — Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) December 31, 2021 Money market funds, included in cash equivalents $ 56,885 $ 56,885 $ — $ — Total $ 56,885 $ 56,885 $ — $ —
Debt Securities, Available-for-Sale [Table Text Block]	Contractual maturity (in days) Amortized Cost Unrealized gains Unrealized losses Fair Value Investments US treasuries 6-153 $ 2,676 $ — $ (2 ) $ 2,674 Foreign treasuries 166 898 — (4 ) 894 Asset-backed securities 107 500 — (3 ) 497 Corporate bonds 1-251 17,244 126 (35 ) 17,335 Total $ 21,318 $ 126 $ (44 ) $ 21,400

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment, Net (Tables)	9 Months Ended
Note 6 - Property and Equipment, Net (Tables)	Sep. 30, 2022
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, December 31, 2022 2021 Laboratory furniture and equipment $ 10,759 $ 11,354 Office furniture and equipment 1,712 1,959 Computer equipment 348 396 Leasehold improvements 11,397 13,130 Property and equipment, cost 24,216 26,839 Accumulated depreciation (8,319 ) (7,717 ) Property and equipment, net $ 15,897 $ 19,122

Note 7 - Accrued Expenses (Tabl

Note 7 - Accrued Expenses (Tables)	9 Months Ended
Note 7 - Accrued Expenses (Tables)	Sep. 30, 2022
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, December 31, 2022 2021 Research and development fees $ 5,036 $ 5,682 Compensation expense 3,248 3,581 Accrued license obligations 131 1,541 Accrued accounts payable 1,560 2,980 Lease liabilities 826 1,049 Other current liabilities 581 393 Collaboration cost-sharing obligation — 1,610 Total $ 11,382 $ 16,836

Note 10 - Leases (Tables)

Note 10 - Leases (Tables)	9 Months Ended
Note 10 - Leases (Tables)	Sep. 30, 2022
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating lease costs $ 314 $ 370 $ 943 $ 1,126 Variable lease costs (1) 148 198 446 562 Total lease cost $ 462 $ 568 $ 1,389 $ 1,688 As of September 30, 2022 Weighted-average remaining lease term (years) 9.8 Weighted-average discount rate 10.5 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Total 2022 $ 545 2023 1,934 2024 1,934 2025 1,934 2026 1,934 Thereafter 10,797 Total undiscounted lease payments 19,078 Less: present value adjustment (6,861 ) Present value of lease liabilities $ 12,217

Note 1 - Corporate Information

Note 1 - Corporate Information (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	May 31, 2013
Cash, Cash Equivalents, and Short-Term Investments, Total	$ 69,800		$ 69,800
Net Income (Loss) Attributable to Parent, Total	(9,736)	$ (16,536)	(25,175)	$ (36,206)
Retained Earnings (Accumulated Deficit), Total	$ (282,319)		$ (282,319)		$ (257,144)
Pieris Pharmaceuticals GmbH [Member]
Business Acquisition, Percentage of Voting Interests Acquired						100%

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Lives (Details)	9 Months Ended
	Sep. 30, 2022
Laboratory Equipment [Member] \| Minimum [Member]
Property and equipment, useful life (Year)	8 years
Laboratory Equipment [Member] \| Maximum [Member]
Property and equipment, useful life (Year)	14 years
Office Equipment [Member] \| Minimum [Member]
Property and equipment, useful life (Year)	5 years
Office Equipment [Member] \| Maximum [Member]
Property and equipment, useful life (Year)	13 years
Computer Equipment [Member] \| Minimum [Member]
Property and equipment, useful life (Year)	3 years
Computer Equipment [Member] \| Maximum [Member]
Property and equipment, useful life (Year)	7 years

Note 3 - Revenue (Details Textu

Note 3 - Revenue (Details Textual) $ / shares in Units, $ in Thousands, € in Millions							1 Months Ended			3 Months Ended		9 Months Ended			12 Months Ended
	May 19, 2021 USD ($)	Apr. 24, 2021 USD ($)	Apr. 01, 2021 USD ($) $ / shares shares	Mar. 24, 2021 USD ($) $ / shares shares	Feb. 08, 2018 USD ($)	May 02, 2017 USD ($)	Aug. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Jan. 31, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 EUR (€)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2017 EUR (€)	Jan. 01, 2019 USD ($)
Contract with Customer, Liability, Current										$ 18,498		$ 18,498			$ 25,116
Contract with Customer, Liability, Noncurrent										18,484		18,484			38,403
Contract with Customer, Liability, Revenue Recognized										5,300		19,500
Number of Technology Licenses						5
Revenues, Total										5,370	$ 4,057	20,056		$ 22,975
Increase (Decrease) in Contract with Customer, Liability										0		0
Genentech [Member]
Revenue, Remaining Performance Obligation, Variable Consideration Amount	$ 1,400
Number Of Initial Research Programs	2
Number Of Optional Additional Research Programs	2
Revenue from Contract with Customer, Collaboration Fee On Additional Program	$ 10,000
Revenue from Contract with Customer, Agreement Termination Notice Period Within Material Breach (Day)	90 days
Revenue from Contract with Customer, Agreement Termination Advance Notice Period Before First Commercial Sale (Day)	90 days
Revenue from Contract with Customer, Agreement Termination Advance Notice Period After First Commercial Sale (Day)	180 days
Number of Research Programs	4
Number of Performance Obligations	2
Revenue, Remaining Performance Obligation, Amount										11,900		11,900
Revenues, Total										553	863	2,733		863
Genentech [Member] \| License and Collaboration Agreement [Member]
Number of Performance Obligations	5
Genentech [Member] \| Platform Technology License [Member]
Number of Performance Obligations	2
Genentech [Member] \| Governance Committee Participation [Member]
Number of Performance Obligations	1
Seattle Genetics Inc. [Member]
Number of Performance Obligations					3
Revenue, Remaining Performance Obligation, Amount										16,100		16,100
Contract with Customer, Liability, Current										10,000		10,000
Contract with Customer, Liability, Noncurrent										3,400		3,400
Amended Collaboration Agreement, Resale of Stock, Period (Day)				60 days
Revenues, Total										155	(280)	3,074		424
Seattle Genetics Inc. [Member] \| Private Placement [Member]
Contract with Customer, Liability, Total				$ 3,300
Sale of Stock, Number of Shares Issued in Transaction (in shares) \| shares				3,706,174
Sale of Stock, Consideration Received on Transaction				$ 13,000
Sale of Stock, Price Per Share (in dollars per share) \| $ / shares				$ 3.51
Sale of Stock, Fair Value, Price Per Share (in dollars per share) \| $ / shares				$ 2.61
Seattle Genetics Inc. [Member] \| License and Collaboration Agreement [Member]
Number of Research Programs				3	3
Number of Performance Obligations					6
Revenue from Contract with Customer, Period After Effective Date Agreements May Be Terminated (Month)					12 months
Revenue from Contract with Customer, Agreement Termination Advance Notice Period (Day)					90 days
Revenue from Contract with Customer, Agreement Termination Advance Notice Period If Marketing Approval Obtained (Day)					180 days
Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)					90 days
Revenue from Contract with Customer, Agreement Termination, Additional Notice Period Upon Material Breach (Day)					90 days
Number Of Licenses					3
Number Of Swap Options					2
Seattle Genetics Inc. [Member] \| Platform Technology License [Member]
Number of Performance Obligations					3
Number of Target Programs					3
Seattle Genetics Inc. [Member] \| Governance Committee Participation [Member]
Number of Performance Obligations					1
Seattle Genetics Inc. [Member] \| Other Arrangement [Member]
Number of Research Programs					2
Seattle Genetics Inc. [Member] \| Up-front Payment Arrangement [Member]
Contract with Customer, Liability, Total					$ 1,200,000
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned					$ 4,900
Seattle Genetics Inc. [Member] \| Antibody Target Swap [Member]
Number of Performance Obligations					2
Astra Zeneca A B [Member]
Contract with Customer, Liability, Total										700		700
Research Collaboration Agreement Period (Year)						5 years
Revenue, Remaining Performance Obligation, Amount										6,900		6,900
Contract with Customer, Liability, Current										600		600
Contract with Customer, Liability, Noncurrent										6,300		6,300
Amended Collaboration Agreement, Resale of Stock, Period (Day)			60 days
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation							$ 5,000		$ 4,700
Revenues, Total								$ 13,000		4,404	1,607	9,026		18,309
Number of Discovery Programs Discontinued									1
Capitalized Contract Cost, Amortization										200	200	300		300
Astra Zeneca A B [Member] \| Accounting Standards Update 2014-09 [Member]
Capitalized Contract Cost, Net, Total						$ 1,600				200		200
Capitalized Contract Cost, Gross																		$ 1,100
Astra Zeneca A B [Member] \| Private Placement [Member]
Sale of Stock, Number of Shares Issued in Transaction (in shares) \| shares			3,584,230
Sale of Stock, Consideration Received on Transaction			$ 10,000
Sale of Stock, Price Per Share (in dollars per share) \| $ / shares			$ 2.79
Sale of Stock, Fair Value, Price Per Share (in dollars per share) \| $ / shares			$ 2.60
Astra Zeneca A B [Member] \| License and Collaboration Agreement [Member]
Number of Performance Obligations						16
Revenue from Contract with Customer, Period After Effective Date Agreements May Be Terminated (Month)						12 months
Revenue from Contract with Customer, Agreement Termination Advance Notice Period (Day)						90 days
Revenue from Contract with Customer, Agreement Termination Advance Notice Period If Marketing Approval Obtained (Day)						180 days
Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)						180 days
Revenue from Contract with Customer, Agreement Termination, Additional Notice Period Upon Material Breach (Day)						180 days
Number of Novel Proteins						4
Agreement Termination Notice Period Upon Of Breach Of Payment Obligations (Day)						30 days
Remaining Performance Obligation, Estimated Term (Month)						12 months
Astra Zeneca A B [Member] \| License and Collaboration Agreement [Member] \| Minimum [Member]
Number of Collaboration Products						2
Astra Zeneca A B [Member] \| License and Collaboration Agreement [Member] \| Maximum [Member]
Number of Collaboration Products						4
Number of Programs						2
Number of Research Licenses						4
Astra Zeneca A B [Member] \| Up-front Payment Arrangement [Member]
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation						$ 45,000
Astra Zeneca A B [Member] \| Up-front Payment Arrangement [Member] \| Estimated Development And Manufacturing Services [Member]
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation						14,200
Astra Zeneca A B [Member] \| Up-front Payment Arrangement [Member] \| Sales Milestone Payments [Member]
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation						12,500
Astra Zeneca A B [Member] \| Up-front Payment Arrangement [Member] \| Estimated Phase 2a Services [Member]
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation						4,700
Astra Zeneca A B [Member] \| Additional Other Research Services [Member]
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation						$ 4,700
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]
Number of Performance Obligations																10	10
Revenue, Remaining Performance Obligation, Amount										4,800		4,800
Contract with Customer, Liability, Current										800		800
Contract with Customer, Liability, Noncurrent										3,900		3,900
Contract with Customer, Liability, Revenue Recognized												4,900
Number of Novel Proteins																1	1
Number of Programs																3	3
Revenues, Total										258	$ 1,867	5,223		$ 3,379
Capitalized Contract Cost, Amortization												$ 100
Number of Ongoing Performance Obligations												3	3
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| Accounting Standards Update 2014-09 [Member]
Capitalized Contract Cost, Net, Total										0		$ 0						$ 500
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| License and Collaboration Agreement [Member]
Number of Programs																5	5
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| Collaborative Arrangement [Member]
Revenue from Contract with Customer, Excluding Assessed Tax												3,700	€ 3.3
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| Collaborative Arrangement [Member] \| Minimum [Member]
Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)																90 days	90 days
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| Collaborative Arrangement [Member] \| Maximum [Member]
Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)																120 days	120 days
License [Member] \| Genentech [Member]
Contract with Customer, Liability, Total	$ 20,000
Contract with Customer, Liability, Current										7,100		7,100
Contract with Customer, Liability, Noncurrent										$ 4,800		$ 4,800
License [Member] \| B P Assets X I I Inc [Member]
Revenue, Remaining Performance Obligation, Amount		$ 6,000
Contract with Customer, Asset, after Allowance for Credit Loss, Total		4,000
License [Member] \| B P Assets X I I Inc [Member] \| Exclusive Product License Agreement [Member]
Contract with Customer, Liability, Total		10,000
Revenue, Remaining Performance Obligation, Variable Consideration Amount		352,500
Revenue, Remaining Performance Obligation, Amount		10,000
Revenue from Contract with Customer, Contribution Towards Manufacturing Activities		$ 4,000
Revenue from Contract with Customer, Period After Effective Date Agreements May Be Terminated (Month)		9 months
Revenue from Contract with Customer, Agreement Termination Advance Notice Period (Day)		60 days
Revenue from Contract with Customer, Agreement Termination Advance Notice Period If Marketing Approval Obtained (Day)		120 days
Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)		180 days
Revenue from Contract with Customer, Agreement Termination Notice Period, Non-Payment Of Undisputed Amounts (Day)		60 days
Revenue from Contract with Customer, Agreement Termination, Additional Notice Period Upon Material Breach (Day)		180 days
Revenue from Contract with Customer, Agreement Obligation Cost		$ 4,000
Contract with Customer, Liability, Revenue Recognized															$ 5,700
License [Member] \| Seattle Genetics Inc. [Member] \| Up-front Payment Arrangement [Member]
Revenue from Contract with Customer, Excluding Assessed Tax					$ 30,000
License [Member] \| Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| Up-front Payment Arrangement [Member]
Revenue from Contract with Customer, Excluding Assessed Tax																$ 32,000	€ 30
Research And Development Services [Member] \| Genentech [Member]
Research Collaboration Agreement Period (Year)	3 years
Research And Development Services [Member] \| Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]
Number of Development Programs																2	2
Number of Development Milestones																3	3

Note 3 - Revenue - Disaggregati

Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total revenue		$ 5,370	$ 4,057	$ 20,056	$ 22,975
Seattle Genetics Inc. [Member]
Total revenue		155	(280)	3,074	424
Astra Zeneca A B [Member]
Total revenue	$ 13,000	4,404	1,607	9,026	18,309
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]
Total revenue		258	1,867	5,223	3,379
Genentech [Member]
Total revenue		$ 553	$ 863	$ 2,733	$ 863

Note 3 - Revenue - Potential Mi

Note 3 - Revenue - Potential Milestone Payments Received (Details) - Collaborative Arrangement [Member] $ in Millions	Sep. 30, 2022 USD ($)
Research And Development Milestone Payments [Member]
milestone	$ 2,496
Research And Development Milestone Payments [Member] \| Astra Zeneca A B [Member]
milestone	702
Research And Development Milestone Payments [Member] \| Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]
milestone	118
Research And Development Milestone Payments [Member] \| Seattle Genetics Inc. [Member]
milestone	754
Research And Development Milestone Payments [Member] \| Boston Pharmaceuticals [Member]
milestone	88
Research And Development Milestone Payments [Member] \| Genentech [Member]
milestone	834
Sales Milestone Payments [Member]
milestone	5,328
Sales Milestone Payments [Member] \| Astra Zeneca A B [Member]
milestone	3,925
Sales Milestone Payments [Member] \| Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]
milestone	88
Sales Milestone Payments [Member] \| Seattle Genetics Inc. [Member]
milestone	450
Sales Milestone Payments [Member] \| Boston Pharmaceuticals [Member]
milestone	265
Sales Milestone Payments [Member] \| Genentech [Member]
milestone	$ 600

Note 4 - Grant Income (Details

Note 4 - Grant Income (Details Textual) - Jun. 30, 2021 € in Millions, $ in Millions	USD ($)	EUR (€)
Grants Receivable	$ 17	€ 14.2

Note 5 - Cash, Cash Equivalen_3

Note 5 - Cash, Cash Equivalents and Investments (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Debt Securities, Available-for-Sale, Realized Gain (Loss), Total	$ 200	$ 0	$ 300	$ 0

Note 5 - Cash, Cash Equivalen_4

Note 5 - Cash, Cash Equivalents and Investments - Cash Equivalents and Investments Carried at Fair Value (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair value	$ 21,400
Total	46,583	$ 56,885
Fair Value, Inputs, Level 1 [Member]
Total	28,751	56,885
Fair Value, Inputs, Level 2 [Member]
Total	17,832	0
Fair Value, Inputs, Level 3 [Member]
Total	0	0
Money Market Funds [Member]
Money market funds, included in cash equivalents	25,183	56,885
Money Market Funds [Member] \| Fair Value, Inputs, Level 1 [Member]
Money market funds, included in cash equivalents	25,183	56,885
Money Market Funds [Member] \| Fair Value, Inputs, Level 2 [Member]
Money market funds, included in cash equivalents	0	0
Money Market Funds [Member] \| Fair Value, Inputs, Level 3 [Member]
Money market funds, included in cash equivalents	0	$ 0
US Treasury Securities [Member]
Fair value	2,674
US Treasury Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair value	2,674
US Treasury Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair value	0
US Treasury Securities [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair value	0
Debt Security, Government, Non-US [Member]
Fair value	894
Debt Security, Government, Non-US [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair value	894
Debt Security, Government, Non-US [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair value	0
Debt Security, Government, Non-US [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair value	0
Asset-Backed Securities [Member]
Fair value	497
Asset-Backed Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair value	0
Asset-Backed Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair value	497
Asset-Backed Securities [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair value	0
Corporate Bond Securities [Member]
Fair value	17,335
Corporate Bond Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair value	0
Corporate Bond Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair value	17,335
Corporate Bond Securities [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair value	$ 0

Note 5 - Cash, Cash Equivalen_5

Note 5 - Cash, Cash Equivalents and Investments - Investments (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Amortized cost	$ 21,318
Unrealized gains	126
Unrealized losses	(44)
Fair value	21,400
US Treasury Securities [Member]
Amortized cost	2,676
Unrealized gains	0
Unrealized losses	(2)
Fair value	$ 2,674
US Treasury Securities [Member] \| Minimum [Member]
Contractual Maturity Period (Day)	6 days
US Treasury Securities [Member] \| Maximum [Member]
Contractual Maturity Period (Day)	153 days
Debt Security, Government, Non-US [Member]
Contractual Maturity Period (Day)	166 years
Amortized cost	$ 898
Unrealized gains	0
Unrealized losses	(4)
Fair value	894
Asset-Backed Securities [Member]
Amortized cost	500
Unrealized gains	0
Unrealized losses	(3)
Fair value	497
Corporate Bond Securities [Member]
Amortized cost	17,244
Unrealized gains	126
Unrealized losses	(35)
Fair value	$ 17,335
Corporate Bond Securities [Member] \| Minimum [Member]
Contractual Maturity Period (Day)	1 day
Corporate Bond Securities [Member] \| Maximum [Member]
Contractual Maturity Period (Day)	251 days

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment, Net - Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property and equipment, cost	$ 24,216	$ 26,839
Accumulated depreciation	(8,319)	(7,717)
Property and equipment, net	15,897	19,122
Laboratory Equipment [Member]
Property and equipment, cost	10,759	11,354
Office Equipment [Member]
Property and equipment, cost	1,712	1,959
Computer Equipment [Member]
Property and equipment, cost	348	396
Leasehold Improvements [Member]
Property and equipment, cost	$ 11,397	$ 13,130

Note 7 - Accrued Expenses - Acc

Note 7 - Accrued Expenses - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Research and development fees	$ 5,036	$ 5,682
Compensation expense	3,248	3,581
Accrued license obligations	131	1,541
Accrued accounts payable	1,560	2,980
Lease liabilities	826	1,049
Other current liabilities	581	393
Collaboration cost-sharing obligation	0	1,610
Total	$ 11,382	$ 16,836

Note 8 - Net Loss Per Share (De

Note 8 - Net Loss Per Share (Details Textual) - shares shares in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	38.8	36.7

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Millions				1 Months Ended	9 Months Ended
	Jun. 22, 2022	Jun. 25, 2021	May 20, 2021	Aug. 31, 2021	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Common Stock, Shares Authorized (in shares)					300,000,000	300,000,000
Common Stock, Shares, Outstanding, Ending Balance (in shares)					74,406,253	72,222,661
Common Stock, Shares, Issued (in shares)					74,406,253	72,222,661
Common Stock, Par or Stated Value Per Share (in dollars per share)					$ 0.001	$ 0.001
Preferred Stock, Shares Authorized (in shares)					10,000,000	10,000,000
Preferred Stock, Shares Issued (in shares)					15,617
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					15,617	15,617
Preferred Stock, Par or Stated Value Per Share (in dollars per share)					$ 0.001	$ 0.001
Jefferies L L C [Member] \| At the Market Offering [Member]
Sale of Stock, Authorized Amount				$ 50
Stock Issued During Period, Shares, New Issues (in shares)					2.1
Stock Issued During Period, Value, Issued for Services					$ 7.2
Shares Issued, Price Per Share (in dollars per share)					$ 3.46
Conversion of Common Stock into Series E Preferred Stock [Member]
Conversion of Stock, Shares Converted (in shares)			5,000,000
Conversion of Stock, Shares Issued (in shares)			5,000
Employee Director And Consultant Equity Incentive Plan2020 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)							3,500,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	3,000,000	2,250,000
Employee Director And Consultant Equity Incentive Plan 2019 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)							1,579,678
Series A Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)					85	85
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					85	85
Series B Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)					4,026	4,026
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					4,026	4,026
Series C Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)					3,506	3,506
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					3,506	3,506
Series D Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)					3,000	3,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					3,000	3,000
Series E Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)			5,000
Preferred Stock, Shares Issued (in shares)					5,000	5,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					5,000	5,000

Note 10 - Leases (Details Textu

Note 10 - Leases (Details Textual) $ in Millions		1 Months Ended	3 Months Ended		9 Months Ended
Note 10 - Leases (Details Textual) $ in Millions	Feb. 29, 2020 USD ($) ft²	Feb. 29, 2020 USD ($) ft²	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jul. 31, 2021	Mar. 31, 2019 USD ($)	Aug. 31, 2015 ft²
Operating Lease, Payments \| $			$ 0.5	$ 0.6	$ 1.6	$ 1.9
Hallbergmoos Germany [Member] \| Leases Expected to be Delivered by October 2024 [Member]
Area of Real Estate Property (Square Foot) \| ft²	22,300	22,300
Hallbergmoos Germany [Member] \| Leases with First Right of Refusal for Additional Area [Member]
Area of Real Estate Property (Square Foot) \| ft²	13,400	13,400
Sublease Office Space [Member] \| Boston Massachusetts [Member]
Area of Real Estate Property (Square Foot) \| ft²									3,950
Lessee, Operating Lease, Renewal Term (Month)							10 months
Office and Laboratory Space [Member] \| Hallbergmoos Germany [Member]
Area of Real Estate Property (Square Foot) \| ft²	105,000	105,000
Lessee, Operating Lease, Renewal Term (Month)	60 months	60 months
Number of Agreement Extension Options	2
Lessee, Operating Lease, Monthly Rent Expense \| $		$ 0.2
Security Deposit \| $	$ 0.8	$ 0.8
Tenant Improvements \| $								$ 11.5

Note 10 - Leases - Operating Le

Note 10 - Leases - Operating Lease Costs (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating lease costs		$ 314	$ 370	$ 943	$ 1,126
Variable lease costs (1)	[1]	148	198	446	562
Total lease cost		$ 462	$ 568	$ 1,389	$ 1,688
Weighted-average remaining lease term (years) (Year)		9 years 9 months 18 days		9 years 9 months 18 days
Weighted-average discount rate		10.50%		10.50%

[1]Variable lease costs include certain additional charges for operating costs, including insurance, maintenance, taxes, utilities, and other costs incurred, which are billed based on both usage and as a percentage of the Company’s share of total square footage.

Note 10 - Leases - Maturities o

Note 10 - Leases - Maturities of Operating Lease Liabilities (Details) $ in Thousands	Sep. 30, 2022 USD ($)
2022	$ 545
2023	1,934
2024	1,934
2025	1,934
2026	1,934
Thereafter	10,797
Total undiscounted lease payments	19,078
Less: present value adjustment	(6,861)
Present value of lease liabilities	$ 12,217